Pfizer Candidate Shows Immune Response Across 25 Serotypes in Phase 2
Photo: TokenPost
Pfizer’s experimental pneumococcal vaccine candidate PF-07872412 produced an immune response to all 25 targeted serotypes in a Phase 2 study. The study evaluated a four-dose series. PF-07872412 is a pediatric vaccine candidate. Safety and tolerability were also reported. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
